Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Nifurtimox Formulations in Chagas' Disease
NCT03350295Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nifurtimox in Chagas disease (2 arms), sponsored by Bayer. Primary endpoints: Area under the concentration-time curve from time 0 to the last measurable concentration, Maximum observed drug concentration and 1 more. Started Jun 2018; status: completed.
02
Drugs
nifurtimox
03
Conditions
Chagas disease
Beyond the preview
Go deeper on NCT03350295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350295.